EP
MRNA icon

Edgestream Partners’s Moderna MRNA Stock Holding History

Edgestream Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Buy
31,821
+26,567
+506% +$1.37M 0.07% 489
2026
Q1 		$267K Sell
5,254
-28,698
-85% -$1.34M 0.01% 817
2025
Q4 		$1M Sell
33,952
-88,227
-72% -$2.4M 0.03% 696
2025
Q3 		$3.16M Buy
122,179
+21,449
+21% +$598K 0.09% 403
2025
Q2 		$2.78M Buy
100,730
+2,769
+3% +$72.9K 0.08% 454
2025
Q1 		$2.78M Buy
97,961
+71,544
+271% +$2.54M 0.09% 402
2024
Q4 		$1.1M Sell
26,417
-19,869
-43% -$950K 0.05% 545
2024
Q3 		$3.09M Buy
46,286
+32,202
+229% +$2.96M 0.14% 261
2024
Q2 		$1.67M Buy
+14,084
New +$1.78M 0.08% 389
2024
Q1 		– Sell
-11,088
Closed -$1.1M – 946
2023
Q4 		$1.1M Buy
+11,088
New +$933K 0.08% 415
2022
Q4 		– Sell
-2,040
Closed -$241K – 589
2022
Q3 		$241K Buy
+2,040
New +$310K 0.02% 416

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Edgestream Partners's MRNA Position: Q2 2026 in Review

Edgestream Partners increased its Moderna (MRNA) stake by 506% in Q2 2026, buying an estimated $1.37M and bringing the position to 31,821 shares worth $2.23M. The position accounts for 0.07% of the portfolio, ranked #489.

Edgestream Partners first reported a position in MRNA in Q3 2022 and has held it in 11 quarters since. The position peaked at $3.16M in Q3 2025. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Edgestream Partners held 31,821 shares of Moderna worth $2.23M as of Q2 2026.
  • Edgestream Partners bought 26,567 Moderna shares in Q2 2026, an estimated $1.37M.
  • Moderna made up 0.07% of Edgestream Partners's portfolio in Q2 2026, its #489 holding.
  • Edgestream Partners first reported a position in Moderna in Q3 2022 and has held it in 11 quarters since.
  • Edgestream Partners's Moderna position peaked at $3.16M in Q3 2025.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.